Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Apr 12, 2016 at 9:50 AM EDT

Short Sellers Become More Selective in Major Pharma

The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Lee Jackson | Apr 12, 2016 at 8:25 AM EDT

Top Biotech Picks Highlight Jefferies Growth Stocks to Buy

A new Jefferies research report highlights their top growth picks for this week, and the list is dominated by top…

Chris Lange | Apr 11, 2016 at 1:05 PM EDT

Raptor Pharmaceuticals Drops Despite European Launch

Raptor Pharmaceuticals saw its shares sink on Monday after it announced its first commercial sale of Quinsair in Germany and…

Chris Lange | Apr 11, 2016 at 9:05 AM EDT

Insys Therapeutics Sinks on Missed Revenue Estimates

Insys Therapeutics watched its stock slide early Monday morning following the release of less-than-favorable revenue estimates.

Chris Lange | Apr 10, 2016 at 10:15 AM EDT

4 Key Biopharma Movers of the Past Week

Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs.

Chris Lange | Apr 8, 2016 at 10:05 AM EDT

Why Depomed Is Rising on Activist Pressure

Depomed saw its stock surge early Friday morning following news of an open letter from activist firm Starboard Value.

Trey Thoelcke | Apr 8, 2016 at 7:35 AM EDT

3 Stocks With Catalysts That Could Capitalize on Biotech Momentum

If the momentum in biotech can continue, then companies with catalysts within the next 12 to 18 months could get…

Chris Lange | Apr 7, 2016 at 12:10 PM EDT

Ionis Stumbles on FDA Clinical Hold

Ionis Pharmaceuticals made waves in the market on Thursday following a business update on its IONIS-TTR program.

Chris Lange | Apr 7, 2016 at 12:02 PM EDT

Aeglea BioTherapeutics Enters the Market Way Below Expected Price Range

Aeglea BioTherapeutics entered the market quietly on Thursday morning, with pricing below the expected range of $16 to $18 per…

Lee Jackson | Apr 7, 2016 at 10:55 AM EDT

Health Care IT Needs Are Growing: 3 Top Stocks to Buy Now

It is no secret that we have an aging population, and it requires more and more hospital treatment, whether it…

Chris Lange | Apr 6, 2016 at 11:05 AM EDT

Why Sangamo Shares Could More Than Double

Janney Montgomery Scott reiterated its Buy rating and $15 fair value estimate on Sangamo Biosciences as it brings multiple programs…

Chris Lange | Apr 6, 2016 at 10:05 AM EDT

5 Biotechs With the Most Upside This Earnings Cycle

Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help…

Lee Jackson | Apr 5, 2016 at 9:55 AM EDT

3 Hot Biotechs Highlight Jefferies Growth Stocks to Buy This Week

This week's top U.S. growth calls from the analysts at Jefferies focus on companies that have some outstanding upside potential,…

Chris Lange | Apr 4, 2016 at 10:55 AM EDT

Key Analyst Sees Huge Catalyst in Depomed Patent Suit

At the end of March, a district court granted the request from Depomed and lifted the stay of its patent…

Chris Lange | Apr 4, 2016 at 9:15 AM EDT

Why Aldeyra Therapeutics Could Have Exponential Upside

Not only does Aldeyra Therapeutics have a good cash position, but it also it has a strong pipeline as well.…

1 … 215 216 217 218 219 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Become More Selective in Major Pharma

Top Biotech Picks Highlight Jefferies Growth Stocks to Buy

Raptor Pharmaceuticals Drops Despite European Launch

Insys Therapeutics Sinks on Missed Revenue Estimates

4 Key Biopharma Movers of the Past Week

Why Depomed Is Rising on Activist Pressure

3 Stocks With Catalysts That Could Capitalize on Biotech Momentum

Ionis Stumbles on FDA Clinical Hold

Aeglea BioTherapeutics Enters the Market Way Below Expected Price Range

Health Care IT Needs Are Growing: 3 Top Stocks to Buy Now

Why Sangamo Shares Could More Than Double

5 Biotechs With the Most Upside This Earnings Cycle

3 Hot Biotechs Highlight Jefferies Growth Stocks to Buy This Week

Key Analyst Sees Huge Catalyst in Depomed Patent Suit

Why Aldeyra Therapeutics Could Have Exponential Upside

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Become More Selective in Major Pharma

Top Biotech Picks Highlight Jefferies Growth Stocks to Buy

Raptor Pharmaceuticals Drops Despite European Launch

Insys Therapeutics Sinks on Missed Revenue Estimates

4 Key Biopharma Movers of the Past Week

Why Depomed Is Rising on Activist Pressure

3 Stocks With Catalysts That Could Capitalize on Biotech Momentum

Ionis Stumbles on FDA Clinical Hold

Aeglea BioTherapeutics Enters the Market Way Below Expected Price Range

Health Care IT Needs Are Growing: 3 Top Stocks to Buy Now

Why Sangamo Shares Could More Than Double

5 Biotechs With the Most Upside This Earnings Cycle

3 Hot Biotechs Highlight Jefferies Growth Stocks to Buy This Week

Key Analyst Sees Huge Catalyst in Depomed Patent Suit

Why Aldeyra Therapeutics Could Have Exponential Upside

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation